Skip Navigation Links
Investment in Sensionics (SENS)
05 Aug 2021 (291 views)

Sensionics is a startup that is developing a device to monitor the glucose level of diabetics. It is called a continuous glucose monitor (CGM). 

I watched a few videos on Youtube that explained the prospects for this company.

I invested in the shares of this company during the run up in the stock price and sold off all the shares to realize a total profit of $12,500 USD. 

The stock price went to a high of $5.27 on 16 Feb 2021 and dropped to a low of $1.71 on 13 May.

Recently, the price shot up to $3. 

Earlier this year, the company had filed to the regulatory agency for approval of their CGM device. Approval is expected to be given in August. The investors expect the price to move up when approval is announced.

I bought 10,000 shares at an average price of $3.10. My total investment is $31,000 USD.

The stock price has not moved up since my purchase. 

I will keep the shares until the announcement of approval of the CGM. My target is for an appreciation of 20% in the stock price.

I hope that the price will not collapse after the announcement, as has happened with Cassava Science.

Tan Kin Lian


Investment in Sensionics (SENS)
[Back] [Print]


Sensionics is a startup that is developing a device to monitor the glucose level of diabetics. It is called a continuous glucose monitor (CGM). 

I watched a few videos on Youtube that explained the prospects for this company.

I invested in the shares of this company during the run up in the stock price and sold off all the shares to realize a total profit of $12,500 USD. 

The stock price went to a high of $5.27 on 16 Feb 2021 and dropped to a low of $1.71 on 13 May.

Recently, the price shot up to $3. 

Earlier this year, the company had filed to the regulatory agency for approval of their CGM device. Approval is expected to be given in August. The investors expect the price to move up when approval is announced.

I bought 10,000 shares at an average price of $3.10. My total investment is $31,000 USD.

The stock price has not moved up since my purchase. 

I will keep the shares until the announcement of approval of the CGM. My target is for an appreciation of 20% in the stock price.

I hope that the price will not collapse after the announcement, as has happened with Cassava Science.

Tan Kin Lian